Cargando…
Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomi...
Autores principales: | Gomez, Felicia, Fisk, Bryan, McMichael, Joshua F., Mosior, Matthew, Foltz, Jennifer A., Skidmore, Zachary L., Duncavage, Eric J., Miller, Christopher A., Abel, Haley, Li, Yi-Shan, Russler-Germain, David A., Krysiak, Kilannin, Watkins, Marcus P., Ramirez, Cody A., Schmidt, Alina, Martins Rodrigues, Fernanda, Trani, Lee, Khanna, Ajay, Wagner, Julia A., Fulton, Robert S., Fronick, Catrina C., O'Laughlin, Michelle D., Schappe, Timothy, Cashen, Amanda F., Mehta-Shah, Neha, Kahl, Brad S., Walker, Jason, Bartlett, Nancy L., Griffith, Malachi, Fehniger, Todd A., Griffith, Obi L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648575/ https://www.ncbi.nlm.nih.gov/pubmed/37910143 http://dx.doi.org/10.1158/2767-9764.CRC-23-0140 |
Ejemplares similares
-
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
por: Russler-Germain, David A., et al.
Publicado: (2023) -
Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
por: Freshour, Sharon L., et al.
Publicado: (2023) -
Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
por: Freshour, Sharon L., et al.
Publicado: (2023) -
Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes
por: Barnell, Erica K., et al.
Publicado: (2019) -
Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer
por: Barnell, Erica K., et al.
Publicado: (2022)